Toujeo is insulin glargine, a long-acting basal insulin
The absence of a proven link does not eliminate the need for clinical vigilance when new or worsening gastrointestinal symptoms develop during treatment
How often should weight, blood pressure, glucose, kidney function, or other labs be reviewed
Temporary soreness, redness, or bruising at the injection site Mild itching or swelling at the site Occasional nausea, headache, or lightheadedness shortly after injection Allergic reaction (uncommon) Infection at the injection site if sterile technique is compromised Nutrient imbalance with prolonged, unsupervised use particularly relevant for patients with kidney disease The FDA has warned against unapproved injectable products marketed for fat reduction, citing risks including infection, scarring, and skin deformities